Moreover, because of the high degree of similarity of the FYNB and FYNT isoforms’ catalytic domain [122], some FYN inhibitors developed as non-CNS agents, such as 1 and 2 (Table 2), have been repurposed to treat CNS disorders. The gene discussed is FYN; the disease is central nervous system disorder.